114 related articles for article (PubMed ID: 31850206)
1. A Case of
Mejia Saldarriaga M; Steinberg A; Severson EA; Binder A
Front Oncol; 2019; 9():1303. PubMed ID: 31850206
[TBL] [Abstract][Full Text] [Related]
2. CCDC6: the identity of a protein known to be partner in fusion.
Cerrato A; Merolla F; Morra F; Celetti A
Int J Cancer; 2018 Apr; 142(7):1300-1308. PubMed ID: 29044514
[TBL] [Abstract][Full Text] [Related]
3. Response to Pralsetinib in Multi-Drug-Resistant Breast Cancer With CCDC6-RET Mutation.
Zhao J; Xu W; Zhuo X; Liu L; Zhang J; Jiang F; Shen Y; Lei Y; Hou D; Lin X; Wang C; Fu G
Oncologist; 2023 May; 28(6):e416-24. PubMed ID: 37141396
[TBL] [Abstract][Full Text] [Related]
4. Emergence of RET rearrangement co-existing with activated EGFR mutation in EGFR-mutated NSCLC patients who had progressed on first- or second-generation EGFR TKI.
Klempner SJ; Bazhenova LA; Braiteh FS; Nikolinakos PG; Gowen K; Cervantes CM; Chmielecki J; Greenbowe JR; Ross JS; Stephens PJ; Miller VA; Ali SM; Ou SH
Lung Cancer; 2015 Sep; 89(3):357-9. PubMed ID: 26187428
[TBL] [Abstract][Full Text] [Related]
5. Identification and characterization of RET fusions in advanced colorectal cancer.
Le Rolle AF; Klempner SJ; Garrett CR; Seery T; Sanford EM; Balasubramanian S; Ross JS; Stephens PJ; Miller VA; Ali SM; Chiu VK
Oncotarget; 2015 Oct; 6(30):28929-37. PubMed ID: 26078337
[TBL] [Abstract][Full Text] [Related]
6. RET fusion as a novel driver of medullary thyroid carcinoma.
Grubbs EG; Ng PK; Bui J; Busaidy NL; Chen K; Lee JE; Lu X; Lu H; Meric-Bernstam F; Mills GB; Palmer G; Perrier ND; Scott KL; Shaw KR; Waguespack SG; Williams MD; Yelensky R; Cote GJ
J Clin Endocrinol Metab; 2015 Mar; 100(3):788-93. PubMed ID: 25546157
[TBL] [Abstract][Full Text] [Related]
7. Role of RET protein-tyrosine kinase inhibitors in the treatment RET-driven thyroid and lung cancers.
Roskoski R; Sadeghi-Nejad A
Pharmacol Res; 2018 Feb; 128():1-17. PubMed ID: 29284153
[TBL] [Abstract][Full Text] [Related]
8. Molecular events in follicular thyroid tumors.
Kroll TG
Cancer Treat Res; 2004; 122():85-105. PubMed ID: 16209039
[TBL] [Abstract][Full Text] [Related]
9. RET fusions observed in lung and colorectal cancers are sensitive to ponatinib.
Gozgit JM; Chen TH; Song Y; Wardwell S; Wang F; Cai J; Li H; Edgren H; Rivera VM; Pritchard J
Oncotarget; 2018 Jul; 9(51):29654-29664. PubMed ID: 30038711
[TBL] [Abstract][Full Text] [Related]
10.
Arai S; Kita K; Tanimoto A; Takeuchi S; Fukuda K; Sato H; Yano S
Oncotarget; 2017 Sep; 8(43):73766-73773. PubMed ID: 29088743
[TBL] [Abstract][Full Text] [Related]
11. Novel rearrangements involving the RET gene in papillary thyroid carcinoma.
Staubitz JI; Schad A; Springer E; Rajalingam K; Lang H; Roth W; Hartmann N; Musholt TJ
Cancer Genet; 2019 Jan; 230():13-20. PubMed ID: 30466862
[TBL] [Abstract][Full Text] [Related]
12. Antitumor activities of the targeted multi-tyrosine kinase inhibitor lenvatinib (E7080) against RET gene fusion-driven tumor models.
Okamoto K; Kodama K; Takase K; Sugi NH; Yamamoto Y; Iwata M; Tsuruoka A
Cancer Lett; 2013 Oct; 340(1):97-103. PubMed ID: 23856031
[TBL] [Abstract][Full Text] [Related]
13. Acute Lymphoblastic Leukemia Patient with Variant ATF7IP/PDGFRB Fusion and Favorable Response to Tyrosine Kinase Inhibitor Treatment: A Case Report.
Zhang G; Zhang Y; Wu J; Chen Y; Ma Z
Am J Case Rep; 2017 Nov; 18():1204-1208. PubMed ID: 29133777
[TBL] [Abstract][Full Text] [Related]
14. Ccdc6 knock-in mice develop thyroid hyperplasia associated to an enhanced CREB1 activity.
Leone V; Langella C; Esposito F; Arra C; Palma G; Rea D; Paciello O; Merolla F; De Biase D; Papparella S; Celetti A; Fusco A
Oncotarget; 2015 Jun; 6(17):15628-38. PubMed ID: 25970781
[TBL] [Abstract][Full Text] [Related]
15. Successful long-term treatment of non-small cell lung cancer positive for
Takeda M; Sakai K; Nishio K; Nakagawa K
Onco Targets Ther; 2019; 12():5355-5358. PubMed ID: 31360064
[TBL] [Abstract][Full Text] [Related]
16. The clonal evolution of two distinct T315I-positive BCR-ABL1 subclones in a Philadelphia-positive acute lymphoblastic leukemia failing multiple lines of therapy: a case report.
De Benedittis C; Papayannidis C; Venturi C; Abbenante MC; Paolini S; Parisi S; Sartor C; Cavo M; Martinelli G; Soverini S
BMC Cancer; 2017 Aug; 17(1):523. PubMed ID: 28779753
[TBL] [Abstract][Full Text] [Related]
17. The rationale for druggability of CCDC6-tyrosine kinase fusions in lung cancer.
Cerrato A; Visconti R; Celetti A
Mol Cancer; 2018 Feb; 17(1):46. PubMed ID: 29455670
[TBL] [Abstract][Full Text] [Related]
18. CCDC6, a gene product in fusion with different protoncogenes, as a potential chemotherapeutic target.
Laxmi A; Gupta P; Gupta J
Cancer Biomark; 2019; 24(4):383-393. PubMed ID: 30909182
[TBL] [Abstract][Full Text] [Related]
19. Ponatinib is a potent inhibitor of wild-type and drug-resistant gatekeeper mutant RET kinase.
Mologni L; Redaelli S; Morandi A; Plaza-Menacho I; Gambacorti-Passerini C
Mol Cell Endocrinol; 2013 Sep; 377(1-2):1-6. PubMed ID: 23811235
[TBL] [Abstract][Full Text] [Related]
20. ANKRD26-RET - A novel gene fusion involving RET in papillary thyroid carcinoma.
Staubitz JI; Musholt TJ; Schad A; Springer E; Lang H; Rajalingam K; Roth W; Hartmann N
Cancer Genet; 2019 Oct; 238():10-17. PubMed ID: 31425920
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
